Payment overview · 2025
General Payments
$778.52
39 reported records · 10 companies
Healthcare provider profile · identity verified
Andre Nye, MD
Allopathic & Osteopathic Physicians|Family Medicine · NAPLES, FL · NPI 1912077538
Verified facts
What the public records show
CMS Open Payments records show Andre Nye, MD received $778.52 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $281.78 | 36.2% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.68 | 17.8% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.80 | 10.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.28 | 9.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.57 | 6.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.12 | 5.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.73 | 4.5% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.53 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.75 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.28 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $778.52 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.95 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.70 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.71 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.71 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.40 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.30 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.30 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.39 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.73 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.57 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.12 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 241 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
241 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 515 | 185 |
| Lisinopril | Lisinopril | 373 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 257 | 97 |
| Ozempic | Semaglutide | 241 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 82 |
| Losartan Potassium | Losartan Potassium | 182 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 61 |
| Famotidine | Famotidine | 136 | 54 |
| Metformin Hcl | Metformin Hcl | 131 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 39 |
| Potassium Chloride | Potassium Chloride | 115 | 42 |
| Furosemide | Furosemide | 88 | 37 |
| Azithromycin | Azithromycin | 87 | 74 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 85 | 70 |
| Alprazolam | Alprazolam | 84 | 39 |
| Mounjaro | Tirzepatide | 82 | 21 |
| Omeprazole | Omeprazole | 81 | 31 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 80 | 80 |
| Gabapentin | Gabapentin | 80 | 28 |
| Carvedilol | Carvedilol | 78 | 26 |
| Prednisone | Prednisone | 76 | 43 |
| Allopurinol | Allopurinol | 72 | 26 |
| Eliquis | Apixaban | 70 | 21 |
| Trazodone Hcl | Trazodone Hcl | 70 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 29 |
| Meloxicam | Meloxicam | 54 | 23 |
| Simvastatin | Simvastatin | 53 | 17 |
| Celecoxib | Celecoxib | 52 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 24 |
| Estradiol | Estradiol | 49 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 25 |
| Alendronate Sodium | Alendronate Sodium | 46 | 19 |
| Sertraline Hcl | Sertraline Hcl | 44 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Mupirocin | Mupirocin | 42 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 30 |
| Dexamethasone | Dexamethasone | 39 | 36 |
| Levofloxacin | Levofloxacin | 37 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 15 |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 26 |
| Azelastine Hcl | Azelastine Hcl | 30 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 14 |
| Tramadol Hcl | Tramadol Hcl | 26 | 15 |
| Finasteride | Finasteride | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | 11 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | 12 |
| Fluconazole | Fluconazole | 24 | 17 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 19 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 21 | 21 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Nystatin | Nystatin | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Yuvafem | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $778.52 · 39 records | Novo Nordisk Inc | CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error